TickerCNTA
SectorBiotechnology
Mkt cap$6.1B
EV / EBITDAN/A
PostureHigh Velocity
Composite70/100
LensTarget-side

SE-Cluster Research·Issuer Brief·Q2 2026CIK 1847903

Centessa Pharmaceuticals PLC

CNTAHIGH VELOCITYFILING INTENSITY

Centessa Pharmaceuticals PLC reads as High Velocity (composite 70/100); pressure / disclosure signals dominate the posture this cycle · primary market Healthcare.

Lens

Disclosed M&A capital (2023–2025)

N/A

−99%

vs N/A in 2020–2022

Disclosed transactions

N/A

−99%

0/3 active fiscal years in window

Buyer archetype

Programmatic Roll-Up

High recurring acquisition cadence, usually with many smaller targets.

Composite score

/100

High Velocity dominates · Filing Intensity

Financial snapshotRevenueN/A
EBITDAN/A
Enterprise value$6.1B
EV / RevenueN/A
EV / EBITDAN/A
P/EN/A
Cash$62M
Total debt$110M
as of 2026-05-10

§ I·SE-Cluster Issuer Brief

Behavioral posture, nine reads.

Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.

Active Acquirer

24/100

Companies actively deploying disclosed capital into M&A

$290M disclosed buyer spend

Buyer Cadence

21/100

Buyer-side companies with recent filing activity

Filed within 33d
64 8-Ks

Target Probability

36/100

Issuers showing target-side patterns from filings

Control-process language
1 activism filings

Spin/Carve

0/100

Issuers showing spin-off, carve-out, or sum-of-parts posture

1 activism filings

Pressure Watch

34/100

Issuers facing activism, governance, or control pressure

1 activism filings
Latest activism 5y ago; discounted
Control-process filings

Distress Watch

5/100

Issuers showing financial-distress filing patterns

1 activism filings

Restatement Risk

0/100

Issuers with accounting-integrity flags from filings

Capital Velocity

Dominant

70/100

Issuers with the highest filing-activity intensity

64 8-Ks
5 form types

Quiet Power

0/100

Large issuers with low signal volume and clean disclosure cadence

Enterprise value $6.1B
10-Q 35d ago
4 active signals

§ II·SE-Cluster Issuer Brief

Capital cadence.

Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.

Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $290M · Peak count: 11

FY	Disclosed buys	Disclosed spend	Avg ticket	Audited tier
2025	N/A	N/A	N/A	N/A
2024	N/A	N/A	N/A	N/A
2023	N/A	N/A	N/A	N/A
2022	N/A	N/A	N/A	N/A
2021	11	$290M	$26M	N/A
2020	N/A	N/A	N/A	N/A

§ III·SE-Cluster Issuer Brief

Strategy posture.

The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.

Archetype mix

Platform
100%

Strategy keywords

Terms recurring across recent 10-K acquisition disclosures.

platform

§ IV·SE-Cluster Issuer Brief

Filing language.

Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.

“Centessa Pharmaceuticals plc was formed in October 2020 with the purpose of bringing impactful new medicines to patients by combining the primary strengths of the asset-centric venture capital model with the benefits of diversification and scale typically attributed to traditional large R&D organizations.”

10-KFY2021

“Medicxi formed Centessa with a view to ultimately acquiring several pre-revenue, development stage biotech companies, each of which was either controlled by and/or invested in by a fund affiliated with Medicxi or Index Ventures.”

10-KFY2021

“Our UK business is operated by Centessa Pharmaceuticals (UK) Limited, (“CPUK”), (formerly Centessa Limited) directly and, in respect of the SerpinPC program, through its wholly owned UK subsidiary, ApcinteX Limited. In mid-2023, we implemented a corporate consolidation of our UK businesses in order to simplify our administrative operations, obtain operational efficiencies and generate administrative cost savings and improve the overall control environment. This has resulted in the business and assets of our UK subsidiaries, Z Factor Limited, Centessa Pharmaceuticals (Morphogen-IX) Limited, Capella Bioscience Ltd, LockBody Therapeutics Ltd, Inexia Limited, Centessa Pharmaceuticals (Orexia) Limited and Janpix Limited being transferred to CPUK. Subsequently, on December 26, 2023, Inexia Limited, Janpix Limited, Ultrahuman Two Limited and Ultrahuman Four Limited were dissolved using the voluntary strike off procedure in sections 1003 to 1011 of the UK Companies Act 2006. On December 17, 2024, Centessa Pharmaceuticals (Morphogen-IX) Limited, Capella Bioscience Ltd, LockBody Therapeutics Ltd, and Centessa Pharmaceuticals (Orexia) Limited were dissolved using the voluntary strike off procedure in sections 1003 to 1011 of the UK Companies Act 2006. We intend to dissolve Z Factor Limited over the coming months using the voluntary strike off procedure in sections 1003 to 1011 of the UK Companies Act 2006. CPUK is a wholly owned subsidiary of Centessa Pharmaceuticals plc. CPUK was incorporated in 2020 under the laws of England and Wales with primary operations in the United Kingdom. ApcinteX Limited was incorporated in 2014 under the laws of England and Wales with primary operations in the United Kingdom.”

10-KFY2024

§ V·SE-Cluster Issuer Brief

Market context.

Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.

Primary market

Healthcare

Market spend (2023–2025): $195B
Market spend (2020–2022): $253.6B
Recent vs prior: −23%
Issuer rank in market: N/A
Share of market capital: 0.0%

Valuation positioning

N/AEV / EBITDA

CNTA trades at a -35.8-turn discount to the Healthcare peer median of 12.9×.

EV / Revenue: N/A
Net debt / EBITDA: N/A
Peer median EV / EBITDA: 12.9×

Trading comparables

FMP market data · 2026-05-10

Company	EV / EBITDA	EV / Rev	Net debt / EBITDA	Revenue	M&A 2023–2025
AbbVie Inc.ABBV	23.4×	6.7×	3.1×	$62.8B	$18B
UnitedHealth Group IncorporatedUNH	17.2×	0.9×	1.9×	$449.7B	$28.1B
Amgen Inc.AMGN	12.9×	6.0×	2.6×	$37.2B	$26.7B
Elevance Health, Inc.ELV	11.7×	0.5×	2.5×	$200.4B	$6.4B
HCA Healthcare, Inc.HCA	9.3×	1.9×	2.8×	$76.4B	$1.3B

Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.

§ VI·SE-Cluster Issuer Brief

Buyer landscape.

Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.

Likely buyers

No public buyers surface as a strong target-side fit on current signal.

Likely sellers / divestiture partners

No reciprocal divestiture / strategic-alternatives matches identified.

§ VII·SE-Cluster Issuer Brief

Filing activity & signal stream.

Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.

Filing cadence

10-K (annual)62026-03-31
10-Q (quarterly)172026-05-05
8-K (event)642026-03-31
Proxy / DEF 14A182026-05-07
Activism (13D / DFAN / PREC)12021-06-11

Signals on file

elevated
Activism on file
2021-06-11
1 activist filing on file (13D, DFAN14A, PREC14A series).
info
Signal
Serial acquisition history
info
Signal
10-K strategy themes
info
Signal
Recent transaction activity

§ VIII·SE-Cluster Issuer Brief

Audited corpus.

No audited record on file for this CIK in the current v6 corpus.

This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.

Search